Assess whether a CMC change is a comparability or a new product (ae7548)

Situation

After an AdCom briefing document that overstates subgroup findings, complete-response-letter deficiency list is what clinical-development physician can touch in a biologics company planning a biosimilar pathway. Pharma & Life Sciences will live with A CMC change is a comparability versus A new product on this Clinical and Evidence Strategy file.

Decision

Clinical-development physician in a biologics company planning a biosimilar pathway must choose A CMC change is a comparability / A new product using complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize A CMC change is a comparability now; complete-response-letter deficiency list already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep A new product in force until complete-response-letter deficiency list is completed after an AdCom briefing document that overstates subgroup findings for clinical-development physician.
• Treat complete-response-letter deficiency list as A CMC change is a comparability because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page a CMC change is turns on in complete-response-letter deficiency list.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against an AdCom briefing document that overstates subgroup findings and write the one fact that would move a CMC change is for clinical-development physician.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.